This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (11)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Sexual assault nurse examiners working for the San Francisco Department of Public Health at San Francisco General Hospital have offered human immunodeficiency virus (HIV) postexposure prophylaxis (PEP) to survivors of sexual assault since April 1998. Survivors who choose to initiate PEP are given zidovudine (300 mg, twice daily) and lamivudine (150 mg, twice daily) in a combination pill for 10 days. At a follow-up visit 7 to 10 days later, an additional 18 days of the same PEP medications are offered. However, characteristics of those who choose to initiate and complete PEP have not been well described.

Methods

We conducted a retrospective review of charts of patients who were treated following sexual assault and who were offered PEP at San Francisco General Hospital between April 1998 and November 1999. We also computed the total cost of PEP medications.

Results
During the study period, 376 individuals were seen for . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Use of Human Immunodeficiency Virus Postexposure Prophylaxis in Adolescent Sexual Assault Victims
Olshen et al.
Arch Pediatr Adolesc Med 2006;160:674-680.
ABSTRACT | FULL TEXT  

Postexposure Prophylaxis in Children and Adolescents for Nonoccupational Exposure to Human Immunodeficiency Virus
Havens and Committee on Pediatric AIDS
Pediatrics 2003;111:1475-1489.
ABSTRACT | FULL TEXT